Norinchukin Bank The Has $40.33 Million Stock Position in Edwards Lifesciences Corporation $EW

Norinchukin Bank The grew its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 2.4% in the third quarter, HoldingsChannel reports. The fund owned 518,511 shares of the medical research company’s stock after buying an additional 12,228 shares during the period. Norinchukin Bank The’s holdings in Edwards Lifesciences were worth $40,325,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of EW. Norges Bank acquired a new stake in Edwards Lifesciences in the 2nd quarter worth about $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in shares of Edwards Lifesciences by 111.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after purchasing an additional 4,805,819 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares during the period. Marshall Wace LLP raised its position in shares of Edwards Lifesciences by 127.5% in the second quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock valued at $539,303,000 after buying an additional 3,864,908 shares in the last quarter. Finally, Viking Global Investors LP bought a new stake in shares of Edwards Lifesciences in the third quarter valued at approximately $238,688,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Truist Financial set a $89.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Wednesday, February 11th. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a report on Monday, January 12th. UBS Group restated a “neutral” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Barclays reaffirmed an “overweight” rating and issued a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Finally, JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $90.00 to $100.00 in a research note on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $96.14.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 24,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the sale, the vice president directly owned 21,266 shares in the company, valued at approximately $1,782,941.44. This represents a 53.02% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at approximately $3,371,239.08. This represents a 24.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 61,718 shares of company stock worth $5,236,281 over the last quarter. 0.34% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

NYSE EW opened at $83.59 on Tuesday. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The company has a 50-day simple moving average of $82.40 and a 200 day simple moving average of $81.60. The company has a market capitalization of $48.55 billion, a PE ratio of 45.68, a price-to-earnings-growth ratio of 2.13 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. During the same period in the prior year, the company earned $0.59 EPS. The firm’s quarterly revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.